Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol

Table 3 Summary of Week 12 and Week 52 predictive factors of response in CZP-treated patients

Response	Week 12	Week 52
ASDAS-MI	- Younger age - Male sex - Elevated CRP - Higher PtGADA at baseline	- MRI+/HLA-B27+ - Higher BASDAI at baseline - Greater Week 12 ASDAS improvement
ASAS40	- Younger age - Male sex	- MRI+/HLA-B27+ - Lower BASMI at baseline - Greater Week 12 PtGADA and ASQoL improvements
BASDAI50	- Younger age - Male sex	- MRI+/HLA-B27+ - MASES = 0 - Greater Week 12 BASDAI and ASQoL improvements
ASDAS-ID	- Younger age - Male sex	- Positive MRI - ≤2 prior NSAIDs - ASDAS-ID at Week 12 - Lower BASFI at baseline - Greater Week 12 BASDAI improvement

ASAS40 Assessment of SpondyloArthritis International Society 40%, ASDAS Ankylosing Spondylitis Disease Activity Score, ASDAS-ID ASDAS inactive disease (ASDAS <1.3), ASDAS-MI ASDAS major improvement (reduction in ASDAS ≥2.0), ASQoL Ankylosing Spondylitis Quality of Life, BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50%, BASMI Bath Ankylosing Spondylitis Metrology Index, HLA-B27 human leukocyte antigen-B27, MRI magnetic resonance imaging, MASES Maastricht Ankylosing Spondylitis Enthesitis Score (range 0−13), NSAID non-steroidal anti-inflammatory drug, PtGADA Patient Global Assessment of Disease Activity

ISSN: 1478-6362